Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2017 Feb 1;16(3):417–427. doi: 10.1158/1535-7163.MCT-16-0498

Figure 2. Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth.

Figure 2

C57BL/6 mice were injected subcutaneously with B16F10 cells on day 0 and were treated twice per week (Tuesdays and Fridays) with selinexor and immune checkpoint blockade (or appropriate vehicle/isotype control) beginning when tumors became palpable. (a) Selinexor + anti-PD-1. (b) Selinexor + anti-PD-L1. (c) Selinexor + anti-CTLA4. n=6 mice per group. Mean + S.D. *, p<0.05 between selinexor + checkpoint blockade antibody (anti-PD-1, anti-CTLA4, or anti-PD-L1 (100 µg)) and selinexor + isotype control; $, p<0.05 between selinexor + checkpoint blockade antibody (anti-PD-1, anti-CTLA4, or anti-PD-L1 (100 µg)) and vehicle + checkpoint blockade antibody; †, p<0.05 between selinexor + isotype control and vehicle/isotype control; ‡, p<0.05 between selinexor + checkpoint blockade antibody (anti-PD-1, anti-CTLA4, or anti-PD-L1 (100 µg)) and vehicle/isotype control; **, p<0.05 between selinexor + anti-PD-L1 (200 µg) and vehicle + isotype control. Arrows indicate when treatment was initiated.